Clinical Trials for Gallbladder Cancer

A Phase 3, Multicenter, Randomized, Open-label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients With Previously Treated Advanced Biliary Tract Cancer

TrialFetch AI summary: Adults with metastatic or locally advanced/unresectable biliary tract cancer (intrahepatic/extrahepatic cholangiocarcinoma or gallbladder cancer) and ECOG 0–1 whose disease has progressed after exactly one prior platinum-based systemic regimen for advanced disease (prior matched targeted therapy for actionable alterations and/or PD-1/PD-L1 for MSI-H allowed). Patients are randomized to nanvuranlat, an IV small-molecule LAT1 (SLC7A5) amino acid transporter inhibitor intended to disrupt essential amino acid uptake and downstream mTOR signaling, versus physician’s choice of FOLFOX, FOLFIRI, or best supportive care (with initial dose-regimen selection followed by confirmatory comparison).

ClinicalTrials.gov ID: NCT07265674

Phase II Prospective, Open Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Randomizes adults with ctDNA-negative, oligometastatic stage IV foregut adenocarcinoma after ≥4 months of non-progressing systemic therapy to definitive local cytoreduction of all known primary/metastatic sites versus continued standard systemic therapy. Local treatment may include surgery, radiation, ablation, or embolization, with serial tumor-informed Signatera ctDNA monitoring in both arms.

ClinicalTrials.gov ID: NCT07282912